# name
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation,
                exercise capacity, and physical activity in patients with COPD

# metadata.dc.description.abstract[].value
The Phase IV, 8-week, randomized, double-blind,
                placebo-controlled ACTIVATE study (NCT02424344) evaluated the
                effect of aclidinium/formoterol (AB/FF) 400/12 mug twice daily
                on lung hyperinflation, exercise capacity, and physical activity
                in patients with moderate-to-severe COPD. Patients received
                AB/FF (n=134) or placebo (n=133) (1:1) via the
                Genuair/Pressair(R) dry powder inhaler for 8 weeks. From Weeks 5
                to 8, all patients participated in behavioral intervention (BI;
                daily messages providing step goals). The primary end point was
                trough functional residual capacity (FRC) at Week 4. Exercise
                endurance time and physical activity were assessed at Week 4
                (pharmacotherapy only) and at Week 8 (8 weeks of pharmacotherapy
                plus 4 weeks of BI). Other end points included post-dose FRC,
                residual volume, and inspiratory capacity (IC) at rest and
                during exercise. After 4 weeks, trough FRC improved with AB/FF
                versus placebo but did not reach significance (125 mL;
                P=0.0690). However, post-dose FRC, residual volume, and IC at
                rest improved significantly with AB/FF at Week 4 versus placebo
                (all P<0.0001). AB/FF significantly improved exercise
                endurance time and IC at isotime versus placebo at Week 4
                (P<0.01 and P<0.0001, respectively) and Week 8 (P<0.05
                and P<0.0001, respectively). AB/FF achieved higher step
                counts (P<0.01) with fewer inactive patients (P<0.0001) at
                Week 4 versus placebo. Following BI, AB/FF maintained
                improvements in physical activity at Week 8 and nonsignificant
                improvements were observed with placebo. AB/FF 400/12 mug
                demonstrated improvements in lung hyperinflation, exercise
                capacity, and physical activity versus placebo that were
                maintained following the addition of BI. A 4-week period of BI
                might be too short to augment the improvements of physical
                activity observed with AB/FF.

# metadata.dc.relation.isformatof[].value
Reproducció del document publicat a:
                http://dx.doi.org/10.2147/COPD.S143488

# metadata.dc.relation.ispartof[].value
International Journal of Chronic Obstructive Pulmonary Disease,
                2017, vol. 12, num. , p. 2545-2558

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation,
                exercise capacity, and physical activity in patients with COPD